Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
3.
Circ Res ; 61(5 Pt 2): II6-11, 1987 Nov.
Article in English | MEDLINE | ID: mdl-2822286

ABSTRACT

We have found previously that inhibitors of Na+-H+ exchange block platelet arachidonic acid release and subsequent secondary aggregation and serotonin release in response to epinephrine, ADP, and thrombin (0.004 U/ml). The present study demonstrates that the addition of ethylisopropylamiloride, an inhibitor of Na+-H+ exchange, leads to an inhibition of platelet activating factor-induced serotonin release and thromboxane B2 production in human platelets in citrated plasma. In addition, platelet activating factor-induced platelet secretion is blocked by the cyclooxygenase inhibitor indomethacin or the thromboxane antagonist SQ 29548, indicating that arachidonic acid mobilization and metabolism is required for platelet activating factor to elicit platelet activation. Our interpretation of the present findings is that platelet activating factor-induced secretion of dense granules from the human platelet requires the production of cyclooxygenase metabolites from arachidonic acid and that Na+-H+ exchange plays an important, albeit not exclusive, role in mobilization of arachidonic acid in response to platelet activating factor.


Subject(s)
Blood Platelets/physiology , Platelet Activating Factor/physiology , Protons , Sodium/blood , Amiloride/analogs & derivatives , Amiloride/pharmacology , Arachidonic Acid , Arachidonic Acids/blood , Blood Platelets/drug effects , Bridged Bicyclo Compounds, Heterocyclic , Fatty Acids, Unsaturated , Humans , Hydrazines/pharmacology , Indomethacin/pharmacology , Platelet Aggregation/drug effects , Serotonin/blood , Thromboxane A2/antagonists & inhibitors , Thromboxane B2/blood
4.
Invest Radiol ; 21(2): 137-43, 1986 Feb.
Article in English | MEDLINE | ID: mdl-3007391

ABSTRACT

Nuclear medicine has utilized chromium (Cr) for decades to label red blood cells (RBCs). The purpose of this project was to determine whether sufficient paramagnetic Cr could be bound to red cells to influence proton relaxation significantly. We demonstrated that the T1 and T2 of RBCs can be substantially shortened by labeling them with paramagnetic Cr. Proton relaxation enhancement occurs when red cells are incubated with sodium chromate (VI) over a concentration range of 0.10 mM to 31.6 mM. Labeling with Cr at a concentration of 31.6 mM shortened the T1 of packed cells from 714 msec to 33 msec, and the T2 from 117 msec to 24 msec, as compared with nonlabeled red cells. In vitro hemolysis was significantly increased after labeling at 31.6 mM, but not at lower concentrations. Cr-induced proton relaxation enhancement varied with RBCs from different species, temperature, pH, and length of incubation. T1 values of kidneys containing labeled red cells (303 msec), or labeled cells diluted 10-fold with nonlabeled cells (479 msec), were decreased compared with kidneys containing only nonlabeled cells (600 msec). Finally, preliminary data indicate that the signal intensity of perfused renal tissue is significantly influenced in vivo by infusion of Cr-labeled RBCs. This study demonstrated that Cr labeling of RBCs sufficiently enhances red cell proton relaxation to provide excised organs containing red cells, of which 10% have been Cr-labeled, with shorter T1 and T2 values than organs containing nonlabeled cells. In addition, the ability of labeled cells to alter signal intensity in vivo suggests that Cr may have the potential to become an MRI contrast agent.


Subject(s)
Chromium Radioisotopes , Erythrocytes/metabolism , Image Enhancement , Isotope Labeling , Magnetic Resonance Spectroscopy , Animals , Hemolysis , Humans , Hydrogen-Ion Concentration , Kidney/metabolism , Protons , Rabbits , Temperature , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...